Cargando…

Engineering better chimeric antigen receptor T cells

CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Zhao, Pu, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709221/
https://www.ncbi.nlm.nih.gov/pubmed/33292660
http://dx.doi.org/10.1186/s40164-020-00190-2